Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naratriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 13/20 | 1.00 |
| ▸ | HTR1B known ✓ | P28222 | 13/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | THPO | P40225 | 1/20 | 0.55 |
| ▸ | HTR1F | P30939 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naratriptan SCHEMBL29403931 | 1.00 | HTR1D (1.00) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| Naratriptan SCHEMBL28587084 | 0.99 | HTR1D (0.98) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| Naratriptan SCHEMBL41527 | 0.99 | HTR1D (0.98) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| Naratriptan SCHEMBL30903899 | 0.99 | HTR1D (0.98) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| Naratriptan SCHEMBL12803311 | 0.99 | HTR1D (0.98) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| Naratriptan SCHEMBL41528 | 0.98 | HTR1D (0.96) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| SCHEMBL9272206 | 0.94 | HTR1D (0.88) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9274904 | 0.93 | HTR1D (0.86) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| SCHEMBL11946673 | 0.92 | HTR1D (0.84) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 | |
| SCHEMBL12936350 | 0.90 | HTR1D (0.81) | HTR1DHTR1BHTR1ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13850 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075410-A | Dry powder composition for intranasal delivery | — | 2026-05-26 | — | — | CN | claimed |
| US-20260131089-A1 | DRUG DELIVERY DEVICES AND METHODS FOR ADMINISTERING SUBSTANCES TO A BODY CAVITY BY HETEROGENOUS AEROSOLIZATION FOR TREATMENT OF BINGE-EATING DISORDERS AND/OR OBESITY | APTARGROUP, INC. (US) | 2026-05-14 | — | — | US | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| EP-4734974-A1 | CANNABINOID COMPOSITION FOR USE IN THE TREATMENT OF PAIN AND/OR INFLAMMATION | Mabewo Phytopharm AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090164-A1 | COMPOSITIONS COMPRISING ELISMETREP AND A SECOND THERAPEUTIC AGENT FOR TREATING OR PREVENTING MIGRAINE OR PAIN | KALLYOPE, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-2026042047-A1 | COMPOSITIONS AND ARTICLES COMPRISING REVERSIBLE COMPLEXES OF CROSSLINKED CARRAGEENAN | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| EP-4698530-A1 | NK3 MODULATORS AND USES THEREOF | Kallyope, Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| EP-4681714-A2 | METHODS OF TREATING THE SYMPTOMS OF AUTISM SPECTRUM DISORDER | MapLight Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | claimed |
| US-12515030-B2 | Transdermal drug delivery devices and methods | MORNINGSIDE VENTURE INVESTMENTS LIMITED (MC) | 2026-01-06 | — | — | US | claimed |
| US-5705506-A | TREATMENT OF MIGRAINES OR HEADACHES | LABORATOIRES GLAXO SA (FR) | 1998-01-06 | — | — | US | claimed |
| US-5693654-A | Medicaments for treating intraocular pressure | GLAXO GROUP LIMITED (GB) | 1997-12-02 | — | — | US | claimed |
| WO-1997033579-A1 | MEDICAMENTS COMPRISING 5HT1-LIKE RECEPTOR AGONISTS WITH AN INCREASED ABSORPTION | GLAXO GROUP LIMITED (GB) | 1997-09-18 | — | — | WO | claimed |
| EP-0671908-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 5-HT 1? RECEPTOR AGONISTS AND ABSORPTION ENHANCERS | GLAXO CANADA INC. (CA) | 1995-09-20 | — | — | EP | claimed |
| EP-0639072-A1 | PHARMACEUTICAL COMPOSITIONS OF ALKYLSULPHONAMIDES 5HT1 AGONISTS FOR RECTAL ADMINISTRATION | LABORATOIRE GLAXO WELLCOME (FR) | 1995-02-22 | — | — | EP | claimed |
| WO-1993024116-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 5-HT1 RECEPTOR AGONISTS AND ABSORPTION ENHANCERS | GLAXO CANADA INC. (CA) | 1993-12-09 | — | — | WO | claimed |
| WO-1993021916-A1 | PHARMACEUTICAL COMPOSITIONS OF ALKYLSULPHONAMIDES 5HT1 AGONISTS FOR RECTAL ADMINISTRATION | LABORATOIRES GLAXO SA (FR) | 1993-11-11 | — | — | WO | claimed |
| EP-0303507-B1 | INDOLE DERIVATIVES | GLAXO GROUP LTD (GB) | 1993-07-28 | — | — | EP | claimed |
| US-4997841-A | Indole derivatives | GLAXO GROUP LIMITED (GB) | 1991-03-05 | — | — | US | claimed |
| EP-0303507-A2 | Indole derivatives | GLAXO GROUP LIMITED (GB) | 1989-02-15 | — | — | EP | claimed |